Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
